Enhanced Copper–Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme | ACS Applied Materials & Interfaces
PDF) Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours | A. Koumarianou - Academia.edu
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis
Anti‐tumour immune response in GL261 glioblastoma generated by Temozolomide Immune‐Enhancing Metronomic Schedule monitored with MRSI‐based nosological images - Wu - 2020 - NMR in Biomedicine - Wiley Online Library
Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells
Hydrolytic instability and low-loading levels of temozolomide to magnetic PLGA nanoparticles remain challenging against glioblastoma therapy - ScienceDirect
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
PDF) Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
Current Treatment Options for the Management of Glioblastoma Multiforme
Phase II trials of metronomic temozolomide schedules for glioblastoma | Download Table
Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients<link href=
PDF) Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors | SpringerLink
Phase II trials of metronomic temozolomide schedules for glioblastoma | Download Table
Enhanced Copper–Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme | ACS Applied Materials & Interfaces
PDF) Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity | springermedizin.de
Frontiers | Temozolomide – Just a Radiosensitizer?
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas | BMC Cancer | Full Text
PDF) Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
JCM | Free Full-Text | Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions | PLOS ONE
